Latest UCB Stories

2010-06-18 07:30:00

BRUSSELS, June 18 /PRNewswire-FirstCall/ -- The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

2010-06-16 08:30:00

ATLANTA, June 16 /PRNewswire-FirstCall/ -- UCB (Euronext: UCB) and Immunomedics, Inc. (Nasdaq: IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE).

2010-06-15 07:30:00

BRUSSELS, June 15 /PRNewswire-FirstCall/ -- New data from a retrospective cohort study showed that up to three quarters of patients with Parkinson's disease (PD) developed gastrointestinal disorders (GID) that can have a substantial adverse effect on major PD-related clinical and health economic outcomes.

2010-06-14 10:30:00

ATLANTA, June 14 /PRNewswire/ -- Lt.

2010-06-14 08:30:00

ATLANTA, June 14 /PRNewswire/ -- UCB today announced the availability of an oral solution formulation of Vimpat® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilepsy age 17 years and older.

2010-05-19 14:16:06

Improved treatment of severe epilepsy could reduce the overall cost of the condition, according to research presented at the annual meeting of the International Society of Pharmacoeconomic Outcomes Research (ISPOR) at the Hilton Atlanta in Atlanta, Georgia.

2010-05-02 08:15:00

ATLANTA, May 2 /PRNewswire/ -- UCB announced today results of an open-label extension study, PRECiSE 4 (P4), of Cimzia® (certolizumab pegol; CZP) demonstrating that Cimzia provides sustained efficacy over four years in moderate to severe Crohn's Disease patients regardless of whether patients were previously treated with infliximab (IFX) or infliximab-naive.

2010-04-14 07:30:00

ATLANTA, April 14 /PRNewswire/ -- Evidence of Neupro® (Rotigotine Transdermal System) improving motor as well as non-motor symptoms of Parkinson's disease was presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada.

2010-04-09 08:16:00

ATLANTA, April 9 /PRNewswire/ -- The antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) will be the subject of numerous studies and analyses at the 62nd annual American Academy of Neurology (AAN) meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17. To view the multimedia assets associated with this release, please click: http://www.prnewswire.com/mnr/vimpat/34012/ "The breadth and depth of Vimpat data being presented at AAN suggests that the neurology...

2010-04-08 07:30:00

ATLANTA, April 8 /PRNewswire/ -- Extensive new data on rotigotine will be presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada between April 10th and 17th, 2010. At a series of oral and poster presentations, leading international investigators will report the latest data on rotigotine in all stages of Parkinson's disease and in moderate to severe Restless Legs Syndrome (RLS). Oral presentations SP710 (5 year) Long-term Safety and Efficacy of Rotigotine in...

Word of the Day
  • A political dynamiter.
The word 'dynamitard' is related to 'dynamite', which comes from a Greek root meaning 'power' and was coined by Alfred Nobel.